Patients randomized to cinacalcet experienced fewer nonatherosclerotic cardiovascular events ( adjusted relative hazard 0.84 , 95 % CI 0.74 to 0.96 ) , while the effect of cinacalcet on atherosclerotic events did not reach statistical significance .